一项关于KIVU-107在局部晚期或转移性实体瘤受试者中开展的研究
KIVU-107在局部晚期或转移性实体瘤受试者中进行的1期剂量探索与剂量扩展研究
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
研究概览
详细说明
Part A: The primary objective of Part A of this study is to evaluate the safety and tolerability of KIVU-107 and to determine the maximum tolerated dose (MTD)/Recommended Dose for Expansion (RDE).
Part B: The primary objective of Part B of this study is to confirm the safety and tolerability of KIVU-107 at the RDE.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Kivu Bioscience (US)
- 电话号码:+1.650.606.5170
- 邮箱:KIVU10701@kivubioscience.com
研究联系人备份
- 姓名:Kivu Bioscience (Australia)
- 电话号码:+61 8 7223 0122
- 邮箱:KIVU10701@kivubioscience.com
学习地点
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚、2050
- 招聘中
- Kivu Trial Site
-
Sydney、New South Wales、澳大利亚
- 招聘中
- Kivu Trial Site
-
-
Queensland
-
Brisbane、Queensland、澳大利亚
- 招聘中
- Kivu Trial Site
-
-
South Australia
-
Adelaide、South Australia、澳大利亚
- 招聘中
- Kivu Trial Site
-
-
Victoria
-
Geelong、Victoria、澳大利亚
- 招聘中
- Kivu Trial Site
-
-
-
-
California
-
Santa Monica、California、美国、90403
- 招聘中
- Kivu Trial Site
-
-
Connecticut
-
New Have、Connecticut、美国、06520
- 招聘中
- Kivu Trial Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female ≥18 years of age
- No therapy of proven efficacy exists for the tumor
- Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.
- Adequate bone marrow, kidney, and liver function
- Measurable disease using RECIST v1.1
- ECOG 0 or 1
- Life expectancy ≥ 3 months
Exclusion Criteria:
- Prior treatment with any ADC with topoisomerase 1 inhibitor payload
- Any PTK7 - targeted therapy
- Uncontrolled cardiovascular disease
- Active Hepatitis B, Hepatitis C, or HIV infection
- History of interstitial lung disease
- Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose Finding
Part A: KIVU-107 Dose Finding - Participants will be treated with KIVU-107 in multiple ascending cohorts. |
KIVU-107 will be administered IV. |
|
实验性的:Dose Expansion
Part B: KIVU-107 Dose Expansion - Participants will be treated with the RDE from Part A. |
KIVU-107 will be administered IV. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
根据CTCAE 5.0版评估的治疗相关不良事件参与者人数
大体时间:最长18个月
|
最长18个月
|
|
|
Part A (Dose Finding): To determine the Maximum Tolerated Dose (MTD)
大体时间:Up to 18 months
|
Number of participants with treatment emergent adverse events |
Up to 18 months
|
|
To evaluate safety and tolerability of KIVU-107
大体时间:Up to 30 months
|
Number of participants with treatment related adverse events as assessed by CTCAE v5.0 |
Up to 30 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
客观缓解率(ORR)指根据RECIST 1.1标准达到完全缓解(CR)或部分缓解(PR)最佳疗效的受试者百分比
大体时间:最长30个月
|
最长30个月
|
|
|
评估接受KIVU-107治疗的参与者体内抗药物抗体变化的免疫原性
大体时间:最长30个月
|
最长30个月
|
|
|
Duration of Response (DOR)
大体时间:Up to 30 months
|
Time from CR or PR to objective disease progression or death to any cause |
Up to 30 months
|
|
Maximum Serum concentration of KIVU-107 (Cmax)
大体时间:21 days
|
PK assessment |
21 days
|
|
Maximum serum concentration of KIVU-107 (Cmin)
大体时间:21 days
|
PK assessment |
21 days
|
|
Maximum Serum concentration of KIVU-107 at Steady State (Cmax, ss)
大体时间:up to 168 days
|
PK assessment |
up to 168 days
|
|
Minimum Serum Concentration of KIVU-107 at Steady State (Cmin, ss)
大体时间:up to 168 days
|
PK assessment |
up to 168 days
|
|
Time of Maximum Serum Concentration of KIVU-107 (Tmax)
大体时间:up to 168 days
|
PK assessment |
up to 168 days
|
|
Time of Minimum Serum Concentration of KIVU-107 (Tmin)
大体时间:up to 168 days
|
PK assessment |
up to 168 days
|
|
Time of Minimum Serum Concentration of KIVU-107 (Tmin, ss)
大体时间:Up to 168 days
|
PK assessment |
Up to 168 days
|
|
Terminal Half-Life (t1/2) of Serum KIVU-107
大体时间:Up to 168 days
|
PK assessment |
Up to 168 days
|
|
Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for KIVU-107
大体时间:21 days
|
PK Assessment |
21 days
|
|
Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for KIVU-107
大体时间:Up to 168 days
|
PK Assessment |
Up to 168 days
|
|
Clearance (CL) of KIVU-107
大体时间:Up to 168 days
|
PK Assessment |
Up to 168 days
|
|
Apparent volume of distribution during the terminal phase (Vz) of KIVU-107
大体时间:Up to 168 days
|
PK Assessment |
Up to 168 days
|
|
Accumulation ration (Rac) of KIVU-107
大体时间:Up to 168 days
|
PK Assessment |
Up to 168 days
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
评估可能预测对KIVU-107应答和/或耐药性的生物标志物,特征化基因组、mRNA和/或蛋白质生物标志物的基线水平和/或变化,以确定与应答或耐药相关的任何特征。
大体时间:最长30个月
|
最长30个月
|
|
|
无进展生存期(PFS)定义为从首次给药至根据RECIST v.1.1标准出现疾病进展或因任何原因导致死亡(以先发生者为准)的时间。
大体时间:最长30个月
|
最长30个月
|
|
|
Overall Survival (OS)
大体时间:Up to 30 months
|
Proportion of participants alive at 1 year from the start of treatment to death from any cause |
Up to 30 months
|
|
Time to Response (TTR)
大体时间:Up to 30 months
|
Time from start of treatment to complete response or partial response |
Up to 30 months
|
|
Disease Control Rate (DCR)
大体时间:Up to 30 months
|
Proportion of participants with CR, PR, or SD |
Up to 30 months
|
合作者和调查者
调查人员
- 学习椅:Louie Naumovski, MD, PhD、Kivu Bioscience
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 病理过程
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 组织学类型的肿瘤
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 肠道肿瘤
- 直肠疾病
- 子宫疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 头颈肿瘤
- 胰腺疾病
- 肿瘤、腺体和上皮
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 肿瘤过程
- 食道疾病
- 肺肿瘤
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 癌
- 肿瘤,鳞状细胞
- 宫颈疾病
- 癌,支气管癌
- 支气管肿瘤
- 子宫肿瘤
- 肿瘤、结缔组织和软组织
- 癌,鳞状细胞
- 食道肿瘤
- 病理状况、体征和症状
- 皮肤和结缔组织疾病
- 头颈部鳞状细胞癌
- 食管鳞状细胞癌
- 结直肠肿瘤
- 卵巢肿瘤
- 乳腺肿瘤
- 肿瘤转移
- 胰腺肿瘤
- 癌,非小细胞肺癌
- 宫颈肿瘤
- 小细胞肺癌
- 肉瘤
- 三阴性乳腺肿瘤
- 子宫内膜肿瘤
其他研究编号
- KIVU-107-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.